(Q64896768)

30 June 2019

title

Cost-utility analysis of vaccination against HPV in Israel. (English)

1 reference

30 June 2019

author

Gary Ginsberg

1

1 reference

30 June 2019

author name string

Menachem Fisher

2

1 reference

30 June 2019

Inbar Ben-Shahar

3

1 reference

30 June 2019

Jacob Bornstein

4

1 reference

30 June 2019

language of work or name

English

0 references

publication date

30 July 2007

1 reference

30 June 2019

published in

Vaccine

1 reference

30 June 2019

volume

25

1 reference

30 June 2019

issue

37-38

1 reference

30 June 2019

page(s)

6677-6691

1 reference

30 June 2019

Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Male circumcision, religion, and infectious diseases: an ecologic analysis of 118 developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Screening for cervical cancer: different problems in the developing and the developed world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

International incidence rates of invasive cervical cancer after introduction of cytological screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Chapter 13: Current findings from prophylactic HPV vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Human papillomavirus and cancer: the epidemiological evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Programme costs in the economic evaluation of health interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Econometric estimation of country-specific hospital costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Cost-effectiveness analysis: can we reduce variability in costing methods?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Development of WHO guidelines on generalized cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Therapeutic implications of patterns of recurrence in cancer of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Interaction of passive smoking with GST (GSTM1, GSTT1, and GSTP1) genotypes in the risk of cervical cancer in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Cochrane Database of Systematic Reviews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

PopMod: a longitudinal population model with two interacting disease states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Cost-effectiveness analyses of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Time costs associated with cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

The current status of HPV and rotavirus vaccines in national immunisation schedules in the EU--preliminary results of a VENICE survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.018

10.1016/J.VACCINE.2007.07.018

7 January 2021

Identifiers

DOI

1 reference

30 June 2019

PubMed ID

17706844

1 reference

30 June 2019